Drug Trial Radar · NCT06644040
A Study of TeriQ Patch in Healthy Adult Female Participants
Last checked: Nov 20, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 25, 2024
Primary completion
Dec 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- QuadMedicineIndustry
- Sponsor type
- Industry
- First posted
- Oct 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be a single center, open-label, active-controlled, 3-way, incomplete block, crossover, randomized, and single escalating dose study.
Conditions
- Osteoporosis
Interventions
TeriQ PatchDrug
Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart. Route of administration- Dermal patch
Teribone Inj.Drug
Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch. Route of administration: Sub-cutaneous Injection
Forteo Inj.Drug
Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch. Route of administration: Sub-cutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Maximum plasma concentration (Cmax)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
- To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Time for maximum plasma concentration (Tmax)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
- To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Area under curve (AUC)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
- To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- half lifeTime frame: 12 timepoints on baseline up to 8 hours post first dose administration
- To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Clearance (CL/F)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
- To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Volume distribution (Vd/F)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
- To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Mean residence rate (MRT)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Linear Clinical Research Ltd.
Joondalup, Western Australia, Australia
Linear Clinical Research Ltd.
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.